Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib, Olmesartan, and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
NCT07810088Phase 2Recruiting
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib, olmesartan in breast cancer. Started Jun 2025; status: recruiting.
02
Drugs
dalpiciclibolmesartan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07810088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07810088.